Thromboprophylaxis during neoadjuvant chemotherapy for bladder cancer reduces thromboembolism and bleeding.
bladder cancer
bleeding
neoadjuvant chemotherapy
radical cystectomy
venous thromboembolic events
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
03 Jul 2024
03 Jul 2024
Historique:
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
To assess the risk of venous thromboembolic events (VTEs) and bleeding with or without thromboprophylaxis during neoadjuvant chemotherapy in bladder cancer patients scheduled for radical cystectomy. We conducted a retrospective cohort study in 4886 patients with non-metastatic bladder cancer undergoing cystectomy across 28 centres in 13 countries between 1990 and 2021. Inverse probability weighting analyses were performed to estimate the effect of thromboprophylaxis on VTE and bleeding. In 147 patients (3%) VTEs were recorded within the first year. These occurred a median (interquartile range [IQR]) of 127 (82-198) days after bladder cancer diagnosis. Bleeding events occurred in 131 patients (3%) within the first year. These occurred a median (IQR) of 101 (83-171) days after cancer diagnosis. In inverse probability weighting analyses, compared to patients without thromboprophylaxis during chemotherapy, patients with thromboprophylaxis had not only a lower risk of VTE (hazard ratio [HR] 0.32, 95% confidence interval [CI] 0.12-0.81; P = 0.016) but also a lower bleeding risk (HR 0.03, 95% CI 0.09-0.12; P <0.0001). The retrospective nature of the study was its main limitation. In this retrospective analysis, the benefit of thromboprophylaxis during neoadjuvant chemotherapy before cystectomy is in line with data from randomised trials in other malignancies. Our data suggest thromboprophylaxis is protective against VTEs and should be the standard of care during neoadjuvant chemotherapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
Bagrodia A, Sukhu R, Winer AG et al. Incidence and effect of thromboembolic events in radical cystectomy patients undergoing preoperative chemotherapy for muscle‐invasive bladder cancer. Clin Genitourin Cancer 2017; 16: e113–e120
Duivenvoorden WC, Daneshmand S, Canter D et al. Incidence, characteristics and implications of thromboembolic events in patients with muscle invasive urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. J Urol 2016; 196: 1627–1633
Khorana AA, Soff GA, Kakkar AK et al. Rivaroxaban for thromboprophylaxis in high‐risk ambulatory patients with cancer. N Engl J Med 2019; 380: 720–728
Carrier M, Abou‐Nassar K, Mallick R et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380: 711–719
Agnelli G, George DJ, Kakkar AK et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601–609
Agnelli G, Gussoni G, Bianchini C et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo‐controlled, double‐blind study. Lancet Oncol 2009; 10: 943–949
Key NS, Khorana AA, Kuderer NM et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 2023; 41: 3063–3071
Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135–1141
Saklad M. Grading of patients for surgical procedures. Anesthesiology 1941; 2: 281–284
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383
Mostofi FK, Sobin LH, Torloni H, World Health Organization. Histological typing of urinary bladder tumours / F. K. Mostofi, in collaboration with L. H. Sobin, H. Torloni and pathologists in fourteen countries. Geneva: World Health Organization, 1973
Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder consensus conference committee. Am J Surg Pathol 1998; 22: 1435–1448
Amin MB, Greene FL, Edge SB et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017; 67: 93–99
Mehran R, Rao SV, Bhatt DL et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736–2747
Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res 2011; 20: 40–49
van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007; 16: 219–242
Connors JM. Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med 2014; 370: 2515–2519
Miest TS, Sharma V, Karnes RJ et al. Incidence and predictors of occult preoperative deep vein thrombosis at radical cystectomy for urothelial carcinoma. Can Urol Assoc J 2021; 15: E471–E475
Schomburg JL, Krishna S, Cotter KJ, Soubra A, Rao A, Konety BR. Preoperative incidence of deep venous thrombosis in patients with bladder cancer undergoing radical cystectomy. Urology 2018; 116: 120–124
Fantony JJ, Gopalakrishna A, Noord MV, Inman BA. Reporting bias leading to discordant venous thromboembolism rates in the United States versus non‐US countries following radical cystectomy: a systematic review and meta‐analysis. Eur Urol Focus 2016; 2: 189–196
Young AM, Marshall A, Thirlwall J et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT‐D). J Clin Oncol 2018; 36: 2017–2023
Buller HR, Decousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415
Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Konstantinides S. The post‐PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev 2014; 28: 221–226
Caprini JA, Botteman MF, Stephens JM et al. Economic burden of long‐term complications of deep vein thrombosis after total hip replacement surgery in the United States. Value Health 2003; 6: 59–74